Oxford BioMedica (OTCMKTS:OXBDF – Get Free Report)’s share price gapped down before the market opened on Thursday . The stock had previously closed at $7.15, but opened at $5.94. Oxford BioMedica shares last traded at $5.83, with a volume of 2,675 shares changing hands.
Wall Street Analysts Forecast Growth
Separately, Zacks Research raised Oxford BioMedica to a “hold” rating in a research note on Wednesday, July 22nd. One analyst has rated the stock with a Hold rating, According to data from MarketBeat, the stock has an average rating of “Hold”.
Check Out Our Latest Stock Report on Oxford BioMedica
Oxford BioMedica Trading Down 5.2%
About Oxford BioMedica
Oxford BioMedica is a clinical-stage gene and cell therapy company headquartered in Oxford, United Kingdom. The company specializes in the development, manufacturing and commercialization of lentiviral vector delivery systems for use in treating serious diseases. Its proprietary LentiVector® platform underpins both in-house development programs and third-party collaborations, enabling the stable integration of therapeutic genes into target cells.
In its research pipeline, Oxford BioMedica is advancing candidates across ophthalmology, neuroscience and oncology indications.
Featured Stories
- Five stocks we like better than Oxford BioMedica
- Insider Sales Eclipse $450M Across 3 AI Winners, With NVIDIA Leading the Pack
- GameStop’s Comeback Case Is Getting Interesting, But eBay Still Looks Stronger
- Why Braze’s Guidance Miss May Be a Gift for Investors
- This Corner of the Market Is Outperforming the Benchmark—And It’s Not AI
Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.
